title: Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.
abstract: Pvs25 is an ookinete surface protein from Plasmodium vivax that is the target of transmission-blocking antibodies. Two immunogenicity trials in rhesus monkeys with a recombinant form of the protein, Pvs25H, were undertaken. Monkeys were vaccinated with Pvs25H adsorbed to Alhydrogel or emulsified in Montanide ISA 720 at 0, 4 and 27 weeks (study 1) or in Montanide ISA 720 at 0 and 18 weeks (study 2) with 1.5 or 15 microg Pvs25H in 0.1 or 0.5 mL of emulsion (four combinations). Immunogenicity was assessed by ELISA and by membrane-feeding experiments using P. vivax-infected blood from human volunteers (studies 1 and 2) or from chimpanzees (study 1). Both vaccine trials generated antibodies that blocked transmission of P. vivax to mosquitoes. Antibody titres and transmission blocking were higher with Montanide ISA 720 than with Alhydrogel in the first trial and with the 15 microg Pvs25H/0.5 mL ISA 720 combination in the second trial.
authors: Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA. asaul@niaid.nih.gov
authors: A
authors: A
authors: Saul
authors: M
authors: M
authors: Hensmann
authors: J
authors: J
authors: Sattabongkot
authors: W E
authors: WE
authors: Collins
authors: J W
authors: JW
authors: Barnwell
authors: J A M
authors: JA
authors: Langermans
authors: Y
authors: Y
authors: Wu
authors: C A
authors: CA
authors: Long
authors: F
authors: F
authors: Dubovsky
authors: A W
authors: AW
authors: Thomas
mesh_terms: D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide / Q000276:immunology; D000818:Animals; D000852:Anopheles / Q000469:parasitology*; D000913:Antibodies, Protozoan / Q000097:blood / Q000276:immunology*; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000276:immunology*; D000954:Antigens, Surface / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006801:Humans; D008253:Macaca mulatta; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016780:Malaria, Vivax / Q000276:immunology* / Q000469:parasitology / Q000635:transmission; D008297:Male; D008353:Mannitol / Q000031:analogs & derivatives / Q000276:immunology; D009829:Oleic Acids / Q000276:immunology; D010966:Plasmodium vivax / Q000254:growth & development / Q000276:immunology*; D011897:Random Allocation; D011994:Recombinant Proteins / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000954:Antigens, Surface; D017780:Malaria Vaccines; D009829:Oleic Acids; C121473:Pvs25 protein, P vivax; D011994:Recombinant Proteins; C001681:mannide monooleate; D008353:Mannitol; D000536:Aluminum Hydroxide